title: Functional recovery after destruction of dopamine systems in the nucleus accumbens of rats. IV. Delay by intra-accumbal treatment with ORG 2766- or alpha-MSH antiserum.
abstract: Rats with 6-OHDA lesions in the nucleus accumbens which were treated intra-accumbally with control serum during the first week following the lesion showed a similar level of motor activity 3 weeks after the lesion as sham-lesioned rats treated with control serum. In 6-OHDA-lesioned rats that were identically treated with antiserum against alpha-MSH or the ACTH-(4-9) analog ORG 2766 motor activity was decreased 3 weeks after the lesion. Intra-accumbal treatment with the antisera did not affect motor activity of sham-lesioned rats. The increased motor activity after apomorphine injection into the nucleus accumbens of control serum-treated 6-OHDA-lesioned rats was not observed in 6-OHDA-lesioned rats treated with the antisera. Furthermore, [3H]haloperidol binding studies showed that the changes in the DA receptor systems in the nucleus accumbens of 6-OHDA-lesioned rats treated with control serum, which may reflect denervation supersensitivity, were not observed in 6-OHDA-lesioned rats treated with the antisera. The present data indicate that the functional recovery and the concurrent development of supersensitive DA receptor systems in the nucleus accumbens of 6-OHDA-lesioned rats are delayed by intra-accumbal treatment with ORG 2766 or alpha-MSH antiserum. This suggests that endogenous ACTH/MSH-like factors may be mediating the recovery processes.
authors.affiliation: Rudolf Magnus Institute for Pharmacology, Medical Faculty, University of Utrecht, The Netherlands.
authors.forename: G
authors.initials: G
authors.lastname: Wolterink
authors.forename: E
authors.initials: E
authors.lastname: Van Zanten
authors.forename: J M
authors.initials: JM
authors.lastname: Van Ree
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism / Q000502:physiology*; D006220:Haloperidol / Q000378:metabolism; D006892:Hydroxydopamines; D007106:Immune Sera / Q000494:pharmacology*; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D016627:Oxidopamine; D010446:Peptide Fragments / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D012686:Septal Nuclei / Q000502:physiology*; D000521:alpha-MSH / Q000276:immunology / Q000502:physiology*
chemical_list: D006892:Hydroxydopamines; D007106:Immune Sera; D010446:Peptide Fragments; C013765:Org 2766; D000521:alpha-MSH; D016627:Oxidopamine; D000324:Adrenocorticotropic Hormone; D006220:Haloperidol; D001058:Apomorphine; D004298:Dopamine